tradingkey.logo

ANI Pharmaceuticals Inc

ANIP
查看详细走势图
82.850USD
+0.020+0.02%
收盘 12/19, 16:00美东报价延迟15分钟
1.86B总市值
48.51市盈率 TTM

ANI Pharmaceuticals Inc

82.850
+0.020+0.02%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+0.02%

5天

+3.06%

1月

+3.14%

6月

+28.13%

今年开始到现在

+49.87%

1年

+52.69%

查看详细走势图

TradingKey ANI Pharmaceuticals Inc股票评分

单位: USD 更新时间: 2025-12-19

操作建议

ANI Pharmaceuticals Inc当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在药品行业排名3/158位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价108.00。中期看,股价处于下降通道。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

ANI Pharmaceuticals Inc评分

相关信息

行业排名
3 / 158
全市场排名
20 / 4582
所属行业
药品

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 9 位分析师
买入
评级
108.000
目标均价
+32.78%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

ANI Pharmaceuticals Inc亮点

亮点风险
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
业绩高增长
公司营业收入稳步增长,连续3年增长94.19%
业绩转亏
公司业绩转亏,最新年度亏损美元
估值高估
公司最新PE估值48.52,处于3年历史高位
机构加仓
最新机构持股21.97M股,环比增加0.07%
先锋集团持仓
明星投资者先锋集团持仓,最新持仓市值1.27M
活跃度增加
近期活跃度增加,过去20天平均换手率1.66

ANI Pharmaceuticals Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

ANI Pharmaceuticals Inc简介

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
公司代码ANIP
公司ANI Pharmaceuticals Inc
CEOLalwani (Nikhil Suresh)
网址https://www.anipharmaceuticals.com/

常见问题

ANI Pharmaceuticals Inc(ANIP)的当前股价是多少?

ANI Pharmaceuticals Inc(ANIP)的当前股价是 82.850。

ANI Pharmaceuticals Inc的股票代码是什么?

ANI Pharmaceuticals Inc的股票代码是ANIP。

ANI Pharmaceuticals Inc股票的52周最高点是多少?

ANI Pharmaceuticals Inc股票的52周最高点是99.500。

ANI Pharmaceuticals Inc股票的52周最低点是多少?

ANI Pharmaceuticals Inc股票的52周最低点是52.500。

ANI Pharmaceuticals Inc的市值是多少?

ANI Pharmaceuticals Inc的市值是1.86B。

ANI Pharmaceuticals Inc的净利润是多少?

ANI Pharmaceuticals Inc的净利润为-20.15M。

现在ANI Pharmaceuticals Inc(ANIP)的股票是买入、持有还是卖出?

根据分析师评级,ANI Pharmaceuticals Inc(ANIP)的总体评级为买入,目标价格为108.000。

ANI Pharmaceuticals Inc(ANIP)股票的每股收益(EPS TTM)是多少

ANI Pharmaceuticals Inc(ANIP)股票的每股收益(EPS TTM)是1.708。
KeyAI